Phase II Study of Venetoclax With Alternative Hypomethylating Agent for Patients With Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure: A University of California Hematologic Malignancies Consortium Protocol
Latest Information Update: 30 May 2024
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary) ; Decitabine
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 28 May 2024 Planned End Date changed from 1 Apr 2025 to 1 Dec 2025.
- 28 May 2024 Planned primary completion date changed from 1 Apr 2024 to 1 May 2025.
- 11 Mar 2022 Status changed from not yet recruiting to recruiting.